This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Shulman, D. I. Articles by Boucek, R. J. Search for Related Content PubMed PubMed Citation Articles by Shulman, D. I. Articles by Boucek, R. J., Jr.

Effects of One Year of Recombinant Human Growth Hormone (GH) Therapy on Cardiac Mass and Function in Children with Classical GH Deficiency

Department of Pediatrics, Divisions of Endocrinology and Cardiology, University of South Florida College of Medicine, Tampa 33612; and All Children’s Hospital, St. Petersburg, Florida 33701

Address all correspondence and requests for reprints to: Dorothy I. Shulman, M.D., Associate Professor of Pediatrics, All Children’s Hospital, 801 6th Street South, St. Petersburg, Florida 33701. E-mail: shulmand{at}allkids.org.

Cardiac mass and function were evaluated in 10 children with classical GH deficiency. Echocardiograms were performed at baseline, 3, 6, and 12 months after initiation of recombinant human (rh) GH therapy (0.3 mg/kg·wk). Before treatment, left ventricular (LV) mass indexed to body surface area (BSA) was low or low normal (<50 g/m²) in five children compared with reference control data. Height SD score (-3.2 ± 0.9 vs. -1.8 ± 1.3 yr; P < 0.01), growth velocity SD score (-2.7 ± 1.6 vs. 5.8 ± 3.1; P < 0.01), LV mass (36 ± 9 vs. 60 ± 30 g; P < 0.02), LV mass/BSA (51 ± 12 vs. 72 ± 11 g/m²; P < 0.01), LV mass/height (36 ± 9 vs. 54 ± 15 g/m; P < 0.02), and LV mass/m^2.7 (36 ± 12 vs. 45 ± 8; P < 0.05) increased significantly with rhGH therapy. Pretreatment LV mass/BSA correlated inversely with fold increase in LV mass/BSA over the year (r = -0.83; P < 0.01). Load-dependent indices of diastolic performance were normal at baseline and did not change with rhGH therapy. Percentage increase of mean velocity of circumferential shortening, an index of systolic function, correlated with fold increase in LV mass/BSA (r = 0.88; P < 0.02) over the year of rhGH administration. LV mass can be lower than predicted for body size in some children with severe GH deficiency but is responsive to rhGH replacement. LV mass/BSA increases into the normal range during the first year of rhGH therapy. The rate of increase of LV mass is greater than the increase in BSA during rhGH treatment, suggesting that GH could also be a trophic factor for the heart.

This work was supported by a grant from The Genentech Foundation.

Abbreviations: BSA, Body surface area; IGFBP, IGF binding protein; LV, left ventricular; mVCF, mean VCF; rh, recombinant human; SDS, SD score; VCF, velocity of circumferential shortening.

This article has been cited by other articles:

				M. Salerno, V. Esposito, V. Farina, G. Radetti, A. Umbaldo, D. Capalbo, L. Spinelli, S. Muzzica, G. Lombardi, and A. Colao Improvement of Cardiac Performance and Cardiovascular Risk Factors in Children with GH Deficiency after Two Years of GH Replacement Therapy: An Observational, Open, Prospective, Case-Control Study J. Clin. Endocrinol. Metab., April 1, 2006; 91(4): 1288 - 1295. [Abstract] [Full Text] [PDF]

				R. Lanes, A. Soros, K. Flores, P. Gunczler, E. Carrillo, and J. Bandel Endothelial Function, Carotid Artery Intima-Media Thickness, Epicardial Adipose Tissue, and Left Ventricular Mass and Function in Growth Hormone-Deficient Adolescents: Apparent Effects of Growth Hormone Treatment on These Parameters J. Clin. Endocrinol. Metab., July 1, 2005; 90(7): 3978 - 3982. [Abstract] [Full Text] [PDF]

				S. E. Lipshultz, S. A. Vlach, S. R. Lipsitz, S. E. Sallan, M. L. Schwartz, and S. D. Colan Cardiac Changes Associated With Growth Hormone Therapy Among Children Treated With Anthracyclines Pediatrics, June 1, 2005; 115(6): 1613 - 1622. [Abstract] [Full Text] [PDF]

				A. Colao, C. Di Somma, F. Rota, R. Pivonello, M. C. Savanelli, S. Spiezia, and G. Lombardi Short-Term Effects of Growth Hormone (GH) Treatment or Deprivation on Cardiovascular Risk Parameters and Intima-Media Thickness at Carotid Arteries in Patients with Severe GH Deficiency J. Clin. Endocrinol. Metab., April 1, 2005; 90(4): 2056 - 2062. [Abstract] [Full Text] [PDF]

				A. Colao, C. Di Somma, A. Cuocolo, M. Filippella, F. Rota, W. Acampa, S. Savastano, M. Salvatore, and G. Lombardi The Severity of Growth Hormone Deficiency Correlates with the Severity of Cardiac Impairment in 100 Adult Patients with Hypopituitarism: An Observational, Case-Control Study J. Clin. Endocrinol. Metab., December 1, 2004; 89(12): 5998 - 6004. [Abstract] [Full Text] [PDF]

				G. Radetti and M. Maghnie Is Growth Hormone Treatment in Young Children Safe for the Heart? J. Clin. Endocrinol. Metab., October 1, 2004; 89(10): 5271 - 5272. [Full Text] [PDF]